ClinicalTrials.gg
RecruitingNCT06257706VECTORSUpdated Jan 15, 2026

VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

A Phase 4 interventional study of Vedolizumab in Moderately to Severely Active Crohn's Disease, Crohn Disease and Disease Crohn, sponsored by Alimentiv Inc.. Recruiting at 69 sites in 13 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by Alimentiv Inc. · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
304
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies testing vedolizumab in Crohn Disease — 10 open to participants now, 12 under way, 7 of them phase 3. vedolizumab · Crohn Disease.

Planned enrollment
9th of 39
304 · median 101
Started
2024
with 2 others
Phase 4
14 of 39
3 open now
Primary completion
2029-01
later than 8 of 11 live
Registered
37th of 39
by date
Lead sponsor
1 of 39
Alimentiv Inc.

Among the 39 studies testing vedolizumab in Crohn Disease, this one is the 9th largest by planned enrollment, is one of 3 that started in 2024, is one of 14 in phase 4, reaches primary completion later than 8 of the 11 other live ones, and was the 37th registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

10 of the 39 studies testing vedolizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About vedolizumab

vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing vedolizumab in Crohn Disease, or all of them as a file.
02

Study summary

Transmural healing (TMH) is recognized as a potentially important measure of Crohn's disease (CD) activity but not a formal target. Observational studies suggest that TMH may be associated with better long-term outcomes. The study will evaluate TMH using noninvasive intestinal ultrasound (IUS), a patient-friendly technique that can be performed routinely in clinical practice. The aim of the study is to determine if treating to a target of corticosteroid-free (CS-free) IUS outcomes + clinical symptoms + biomarkers is superior to a target of clinical symptoms + biomarkers alone in achieving CS-free endoscopic remission measured by the Simple Endoscopic Score for Crohn's Disease (SES-CD).

Qualified participants will be randomly assigned in a 1:1 ratio to one of 2 different target treatment groups.

Group 1: Participants will be treated over 48 weeks to achieve a target of corticosteroid-free IUS-based outcomes + clinical remission + biomarker remission. At Week 22 and 30, the IUS-based component of the target will be IUS response and at Week 38, the final treatment target will be TMH. Group 2: Participants will be treated over 48 weeks to achieve a target of corticosteroid-free clinical remission + biomarker remission.

03

Conditions studied

  • Moderately to Severely Active Crohn's Disease
  • Crohn Disease
  • Disease Crohn

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 18 to 80 years, inclusive, at the time of consent;
  2. Moderately to severely active CD at baseline defined by a CDAI score of 220 to 450 inclusive and SES-CD, excluding the presence of narrowing component, ≥6 (or ≥4 for participants with isolated ileal disease);
  3. BWT on IUS of >4.0 mm in the terminal ileum or any colonic segment (excluding the rectum) as assessed by the mean of 2 longitudinal and 2 cross-sectional measurements of the same segment;
  4. Biologic-naïve or have previous exposure (within the last 5 years of the screening date) to no more than 1 advanced therapeutic compound (approved biologic or small molecule drug) for the treatment of their CD. Note: only approximately 15% to 30% of the enrolled population will have had prior exposure to an advanced therapeutic;
  5. Participants may continue stable dose (initiated at least 4 weeks prior to Screening) of 5-ASA for CD;
  6. Persons of must have a negative serum pregnancy test prior to randomization and must use a highly effective method of throughout the study. Females unable to bear children must have documentation of such in the source records;
  7. Able to participate fully in all aspects of this clinical trial;
  8. Written must be obtained and documented.

Exclusion criteria

Exclusion Criteria:

  1. Current or previous treatment with vedolizumab, etrolizumab, or natalizumab;
  2. Previously exposed to 2 or more compounds or classes of an advanced therapeutic compound (approved biologic or small molecule drug) for the treatment of their CD;
  3. Change to oral therapy dosing within 2 weeks prior to randomization or a corticosteroid dose of >40 mg of prednisone or equivalent at randomization;
  4. Only have inflammation proximal to the terminal ileum that cannot be reached by ileocolonoscopy;
  5. Have a CD complication, such as symptomatic strictures in the small bowel with >3 cm prestenotic dilatation on any imaging modality, requiring procedural intervention;
  6. Previous extensive colonic resection or missing >2 segments out of 5 (terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum), ileorectal anastomosis, or a proctocolectomy;
  7. Ostomy or ileoanal pouch;
  8. Short bowel syndrome;
  9. Fibrotic-only stricture in the ileum or colon without evidence of active inflammation (in the investigator's judgment), including any impassable stenosis;
  10. Abscess >2 cm, detected by IUS or endoscopy; participants with draining fistulas are not excluded;
  11. Serious underlying disease other than CD that, in the opinion of the investigator, may interfere with the participant's ability to participate fully in the study or would compromise participant safety;
  12. Positive stool test for Clostridioides difficile infection (as demonstrated by positive toxin);
  13. Known or or C infection. If a negative test result is available in the 12 months prior to randomization, retesting is not required;
  14. Known active or latent tuberculosis (TB); if a negative test result is available in the 12 months prior to randomization, confirmatory testing (per standard of care) is not required before randomization;
  15. Other systemic or opportunistic infection (including cytomegalovirus), any other extraintestinal infection, or recurring infection within 6 months of randomization;
  16. Has active cerebral/meningeal disease, signs, symptoms, or any history of progressive multifocal leukoencephalopathy (PML) prior to randomization;
  17. , allergy, or intolerance to any of vedolizumab or any other to vedolizumab;
  18. Active severe infection such as sepsis, cytomegalovirus, listeriosis, or opportunistic infection.
  19. Unwillingness to withhold protocol-prohibited medications during the trial;
  20. Concurrent or previous participation in another clinical trial and received any therapy within 30 days prior to randomization;
  21. History of alcohol or drug abuse that in the opinion of the investigator may interfere with the participant's ability to comply with the study procedures;
  22. Prior enrolment in the current study and had received study treatment;
  23. Pregnant, lactating, or intending to become pregnant/impregnate a partner before, during, or within 18 weeks after the last dose; or intending to donate ova or sperm during such time period;
  24. Vaccination with a live or within 4 weeks prior to randomization, or planned vaccination with a live or live-attenuated vaccine during participation in the study;
  25. Any person performing mandatory military service, deprived of liberty, in a residential care setting, or any person who, due to a judicial decision, cannot take part in clinical studies;
  26. The person is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (e.g., spouse, parent, child, sibling).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
304 participants (estimated)

Study arms

  • Other
    Group 1: Corticosteroid-free IUS-based outcomes + clinical remission + biomarker remission

    Group 1 will be treated over 48 weeks to achieve a target of corticosteroid-free IUS-based outcomes + clinical remission + biomarker remission. At Week 22 and 30, the IUS-based component of the target will be IUS response and at Week 38, the final treatment target will be TMH.

    Biological: Vedolizumab

  • Other
    Group 2: Corticosteroid-free clinical remission + biomarker remission.

    Group 2 will be treated over 48 weeks to achieve a target of corticosteroid-free clinical remission + biomarker remission.

    Biological: Vedolizumab

Interventions

  • BiologicalVedolizumab

    All participants will begin a vedolizumab induction regimen of 300 mg IV at Weeks 0, 2, 6, and 10 followed by vedolizumab 300 mg IV every 8 weeks starting at Week 14. Treatment may be modified at Weeks 22, 30, and/or 38 based on the results of the target assessment at each of these time points.

06

What researchers measure

Primary outcomes

  1. Percentage of participants with Corticosteroid-free Endoscopic remission in group 1 and group 2 at week 48

    Corticosteroid-free is defined as not using corticosteroids at the time of the assessment. Endoscopic remission is defined by a total Simple Endoscopic Score for CD (SES-CD) ≤4 and at least a 2-point reduction versus baseline with no subscore greater than 1 in any individual variable. The SES-CD scores 4 endoscopic items (ulcer size, proportion of ulcerated surface, proportion of the surface area affected by any disease lesion, and stenosis) from 0 to 3, with higher scores representing more severe endoscopic disease activity. Each variable is scored for the 5 intestinal segments (ileum, right colon, transverse colon, left colon, and rectum) and summed to provide the total variable score. The sum of each variable score ranges from 0 to 15, except for stenosis (ranges from 0 to 11), because 3 represents a stenosis through which a colonoscope cannot be passed and therefore, can only be observed once. Total SES-CD score is then calculated by summing the item scores (range, 0-56 points).

    Time frame: week 48

Secondary outcomes

  1. Percentage of participants with Corticosteroid-free Transmural healing (TMH)+Endoscopic remission+Clinical remission in group 1 and group 2 at week 48

    Transmural healing is defined by Bowel wall thickness (BWT) ≤3.0 mm and color Doppler signal (CDS) 0 in all evaluable segments assessed by Intestinal Ultrasound. Endoscopic remission is defined by achievement of a total Simple Endoscopic Score for CD (SES-CD) ≤4 and at least a 2-point reduction versus baseline with no subscore greater than 1 in any individual variable. The SES-CD assesses 4 endoscopic variables: the size of ulcers, ulcerated surface, affected surface, and presence of narrowing. Each variable score ranging from 0 to 3. The total SES-CD score is calculated using the sum of all parameter scores in 5 segments: terminal ileum, right colon, transverse colon, left colon, and rectum. Clinical Remission is defined by achievement of Crohn's Disease Activity Index (CDAI) \<150. CDAI consists of eight factors, each summed after adjustment with a weighting factor. Total score ranges from 0 to 600 points. Higher scores indicate more severity.

    Time frame: week 48

  2. Percentage of participants with Corticosteroid-free IUS response+Endoscopic remission+Clinical Remission in group 1 and group 2 at week 48

    IUS response is defined by reduction from baseline of 25% in Bowel Wall thickness (BWT) assessed by Intestinal Ultrasound (IUS). Endoscopic remission is defined by achievement of a total Simple Endoscopic Score for CD (SES-CD) ≤4 and at least a 2-point reduction versus baseline with no subscore greater than 1 in any individual variable. Clinical Remission is defined by achievement of Crohn's Disease Activity Index (CDAI) \<150. The CDAI consists of 8 items including physical examination items, extraintestinal manifestations, the hematocrit, and PRO measures as recorded in the participant diary card for the 7 days prior to the clinic visit. Each item is multiplied by a weighting factor and summed to give a total CDAI score, ranging from 0 to over 600 points, with higher scores representing more severe disease activity.

    Time frame: week 48

  3. Percentage of participants with Corticosteroid-free Endoscopic remission+Clinical Remission in group 1 and group 2 at week 48

    Endoscopic remission is defined by achievement of a total Simple Endoscopic Score for CD (SES-CD) ≤4 and at least a 2-point reduction versus baseline with no subscore greater than 1 in any individual variable. The SES-CD scores 4 endoscopic items (ulcer size, proportion of ulcerated surface, proportion of the surface area affected by any disease lesion, and stenosis) from 0 to 3. Each variable is scored for the 5 intestinal segments (ileum, right colon, transverse colon, left colon, and rectum) and summed to provide the total variable score. Total SES-CD score is then summed up the item scores (range, 0-56 points). Clinical Remission is defined by Crohn's Disease Activity Index (CDAI) \<150. CDAI consists of eight factors, each summed after adjustment with a weighting factor. Total score ranges from 0 to 600 points. Higher scores indicate more severity.

    Time frame: week 48

  4. Percentage of participants with Corticosteroid-free endoscopic response+Clinical response in group 1 and group 2 at week 48

    Endoscopic response is defined by Reduction in total Simple Endoscopic Score for CD (SES-CD) ≥50% from baseline. The SES-CD scores 4 endoscopic items (ulcer size, proportion of ulcerated surface, proportion of the surface area affected by any disease lesion, and stenosis) from 0 to 3, higher scores indicate more severity. Each variable is scored for the 5 intestinal segments (ileum, right colon, transverse colon, left colon, and rectum) and summed to provide the total variable score. The sum of each variable score ranges from 0 to 15, except for stenosis, where it ranges from 0 to 11. Total SES-CD score is then calculated by summing the item scores (range, 0-56 points). Clinical Response is defined by Crohn's Disease Activity Index (CDAI) decrease of ≥100 points from baseline. CDAI consists of eight factors, each summed after adjustment with a weighting factor. Total score ranges from 0 to 600 points. Higher scores indicate more severity.

    Time frame: week 48

  5. Percentage of participants with Corticosteroid-free clinical remission in group 1 and group 2 at Week 14, Week 22 and Week 48.

    Corticosteroid-free is defined as not using corticosteroids for treatment of CD at the time of the assessment. Clinical Remission is defined by achievement of Crohn's Disease Activity Index (CDAI) \<150. The CDAI consists of 8 items including physical examination items, extraintestinal manifestations, the hematocrit, and PRO measures as recorded in the participant diary card for the 7 days prior to the clinic visit. Each item is multiplied by a weighting factor and summed to give a total CDAI score, ranging from 0 to over 600 points, with higher scores representing more severe disease activity.

    Time frame: week 14, week 22 and week 48

  6. Percentage of participants with Corticosteroid-free Clinical Response in group 1 and group 2 at week 14, week 22 and week 48

    Corticosteroid-free is defined as not using corticosteroids for treatment of CD at the time of the assessment. Clinical Response is defined by Crohn's Disease Activity Index (CDAI) decrease of ≥100 points from baseline. The CDAI consists of 8 items including physical examination items, extraintestinal manifestations, the hematocrit, and PRO measures as recorded in the participant diary card for the 7 days prior to the clinic visit. Each item is multiplied by a weighting factor and summed to give a total CDAI score, ranging from 0 to over 600 points, with higher scores representing more severe disease activity.

    Time frame: week 14, week 22 and week 48

  7. Crohn's Disease Activity Index(CDAI) total score and corresponding change from baseline during follow-up (Week 6, Week 14, Week 22, Week 30, Week 38, Week 48, Week 64, Week 80, Week 96) in group 1 and group 2

    Crohn's Disease Activity Index (CDAI) consists of 8 items including physical examination items, extraintestinal manifestations, the hematocrit, and PRO measures as recorded in the participant diary card for the 7 days prior to the clinic visit. Each item is multiplied by a weighting factor and summed to give a total CDAI score, ranging from 0 to over 600 points, with higher scores representing more severe disease activity.

    Time frame: week 6, week 14, week 22, week 30, week 38, week 48, week 64, week 80, week 96

  8. Percentage of participants with Corticosteroid-free endoscopic response in group 1 and group 2 at week 48

    Corticosteroid-free is defined as not using corticosteroids for treatment of CD at the time of the assessment Endoscopic response is defined by Reduction in total Simple Endoscopic Score for CD (SES-CD) ≥50% from baseline. The SES-CD scores 4 endoscopic items (ulcer size, proportion of ulcerated surface, proportion of the surface area affected by any disease lesion, and stenosis) from 0 to 3, with higher scores representing more severe endoscopic disease activity. Each variable is scored for the 5 intestinal segments (ileum, right colon, transverse colon, left colon, and rectum) and summed to provide the total variable score. The sum of each variable score ranges from 0 to 15, except for stenosis, where it ranges from 0 to 11, because 3 represents a stenosis through which a colonoscope cannot be passed and therefore, can only be observed once. Total SES-CD score is then calculated by summing the item scores (range, 0-56 points).

    Time frame: week 48

  9. SES-CD total score and corresponding change from baseline to Week 48 in group 1 and group 2

    The SES-CD scores 4 endoscopic items (ulcer size, proportion of ulcerated surface, proportion of the surface area affected by any disease lesion, and stenosis) from 0 to 3, with higher scores representing more severe endoscopic disease activity. Each variable is scored for the 5 intestinal segments (ileum, right colon, transverse colon, left colon, and rectum) and summed to provide the total variable score. The sum of each variable score ranges from 0 to 15, except for stenosis, where it ranges from 0 to 11, because 3 represents a stenosis through which a colonoscope cannot be passed and therefore, can only be observed once. Total SES-CD score is then calculated by summing the item scores (range, 0-56 points).

    Time frame: week 48

  10. Percentage of participants with Transmural healing (TMH) in group 1 and group 2 at week 48

    Transmural Healing (TMH) is defined by Bowel wall thickness (BWT) ≤3.0 mm and color Doppler signal (CDS) 0 in all evaluable segments assessed by Intestinal Ultrasound

    Time frame: week 48

  11. Percentage of participants with Intestinal Ultrasound (IUS) response in group 1 and group 2 at Week 48

    IUS response is defined by reduction from baseline of 25% in Bowel Wall thickness (BWT) assessed by Intestinal Ultrasound (IUS)

    Time frame: week 48

  12. Bowel Wall Thickness (BWT) measured by Intestinal Ultrasound (IUS) in mm and corresponding change from baseline at Week 48 in group 1 and group 2.

    Time frame: week 48

  13. Color Doppler signal (CDS) and corresponding change from baseline at Week 48 in group 1 and group 2.

    Time frame: week 48

  14. International Bowel Ultrasound Segmental Activity Score (IBUS-SAS) (per segment as well as total) and corresponding change from baseline at Week 48 in group 1 and group 2

    International Bowel Ultrasound Segmental Activity Score (IBUS-SAS) is a 0-100 numerical activity index for Crohn's disease calculated from four Intestinal Ultrasound (IUS) parameters

    Time frame: week 48

  15. Percentage of participants with Transmural healing (TMH) at week 14, week 22, week 30, week 38, and week 48 in group 1

    Transmural Healing (TMH) is defined by Bowel wall thickness (BWT) ≤3.0 mm and color Doppler signal (CDS) 0 in all evaluable segments assessed by Intestinal Ultrasound

    Time frame: week 14, week 22, week 30, week 38, week 48

  16. Percentage of participants with Intestinal Ultrasound (IUS) response at week 14, week 22, week 30, week 38, and week 48 in group 1

    IUS response is defined by reduction from baseline of 25% in Bowel Wall thickness (BWT) assessed by Intestinal Ultrasound (IUS)

    Time frame: week 14, week 22, week 30, week 38, week 48

  17. Bowel Wall Thickness (BWT) measured by Intestinal Ultrasound (IUS) in mm and corresponding change from baseline at week 14, week 22, week 30, week 38, and week 48 in group 1

    Time frame: week 14, week 22, week 30, week 38, week 48

  18. Color Doppler signal (CDS) and corresponding change from baseline at week 14, week 22, week 30, week 38, and week 48 in group 1

    Time frame: week 14, week 22, week 30, week 38, week 48

  19. International Bowel Ultrasound Segmental Activity Score (IBUS-SAS) (per segment as well as total) and corresponding change from baseline at week 14, week 22, week 30, week 38, and week 48 in group 1

    International Bowel Ultrasound Segmental Activity Score (IBUS-SAS) is a 0-100 numerical activity index for Crohn's disease calculated from four Intestinal Ultrasound (IUS) parameters

    Time frame: week 14, week 22, week 30, week 38, week 48

  20. Percentage of participants with Histologic remission at week 48 in group 1 and group 2

    Histologic remission is defined by Robarts Histopathology Index (RHI) score ≤3 (per segment) with subscores of 0 for lamina propria neutrophils and 0 for neutrophils in epithelium, as scored by central reader. The RHI is a validated instrument that measures histologic disease activity and consists of 4 subscores (chronic inflammatory infiltrate, lamina propria neutrophils, neutrophils in epithelium, and erosion or ulceration). Each subscore ranges from 0-3, with higher subscores indicating greater histologic disease activity. The RHI score is calculated as: (1 x chronic inflammatory infiltrate) + (2 x lamina propria neutrophils) + (3 x neutrophils in epithelium) + (5 x erosion or ulceration). The RHI therefore ranges from 0-33, with higher scores indicating greater histologic disease activity.

    Time frame: week 48

  21. Percentage of participants with Histologic response at week 48 in group 1 and group 2

    Histologic response is defined as ≥7-point reduction from baseline in RHI, as scored by a central reader. The RHI is a validated instrument that measures histologic disease activity and consists of 4 subscores (chronic inflammatory infiltrate, lamina propria neutrophils, neutrophils in epithelium, and erosion or ulceration). Each subscore ranges from 0-3, with higher subscores indicating greater histologic disease activity. The RHI score is calculated as: (1 x chronic inflammatory infiltrate) + (2 x lamina propria neutrophils) + (3 x neutrophils in epithelium) + (5 x erosion or ulceration). The RHI therefore ranges from 0-33, with higher scores indicating greater histologic disease activity.

    Time frame: week 48

  22. Percentage of patients with Biomarker remission at week 48, week 64, week 80 and week 96 in group 1 and group 2

    Biomarker remission is defined as Normalization of C-reactive protein (CRP) \<5 mg/mL and fecal calprotectin (FCal) \<250 μg/g

    Time frame: week 48, week 64, week 80, week 96

  23. Percentage of patients with Biomarker response at week 48, week 64, week 80 and week 96 in group 1 and group 2

    Biomarker response is defined as ≥50% reduction from baseline in either C-reactive protein (CRP) or fecal calprotectin (FCal)

    Time frame: week 48, week 64, week 80, week 96

  24. Percentage of participants with C-reactive protein (CRP) response during follow-up (Week 6, week 14, week 22, week 30, week 38, week 48, week 64, week 80 and week 96) in group 1 and group 2

    C-reactive protein (CRP) response is defined by ≥50% reduction from baseline

    Time frame: week 6, week 14, week 22, week 30, week 38, week 48, week 64, week 80, week 96

  25. Percentage of participants with fecal calprotectin (FCal) response during follow-up (Week 6, week 14, week 22, week 30, week 38, week 48, week 64, week 80 and week 96) in group 1 and group 2

    Fecal calprotectin (FCal) response is defined by ≥50% reduction from baseline

    Time frame: week 6, week 14, week 22, week 30, week 38, week 48, week 64, week 80, week 96

  26. Changes in C-reactive protein (CRP) from baseline during follow-up (Week 6, week 14, week 22, week 30, week 38, week 48, week 64, week 80 and week 96) in group 1 and group 2

    Time frame: week 6, week 14, week 22, week 30, week 38, week 48, week 64, week 80, week 96

  27. Changes in fecal calprotectin (FCal) from baseline during follow-up (Week 6, week 14, week 22, week 30, week 38, week 48, week 64, week 80 and week 96) in group 1 and group 2

    Time frame: week 6, week 14, week 22, week 30, week 38, week 48, week 64, week 80, week 96

  28. 2-item Patient-Reported Outcome (PRO-2) score and corresponding changes from baseline during follow-up (Weeks 6, week 14, week 22, week 30, week 38, week 48, week 64, week 80 and week 96) in group 1 and group 2

    The PRO-2 consists of the 2 CDAI component items: daily stool frequency and abdominal pain. Study participants record the number of liquid or very soft stools and rate abdominal pain (range, 0-3) daily in their participant diary for the 7 days prior to a clinic visit, excluding days of bowel preparation and ileocolonoscopy. The stool frequency and abdominal pain scores are calculated as the average scores over the 7-day period.

    Time frame: week 6, week 14, week 22, week 30, week 38, week 48, week 64, week 80, week 96

  29. Symptoms and Impacts Questionnaire for CD (SIQ-CD) score and corresponding changes from baseline during follow-up (Weeks 6, week 14, week 22, week 30, week 38, week 48, week 64, week 80 and week 96) in group 1 and group 2

    SIQ-CD tool consists of a symptom domain, which includes Gastrointestinal (GI), pain and discomfort, nutrition-related, and fatigue-related symptoms; and an impact domain, which includes concepts related to daily activities, nutrition, emotional well-being, and productivity.

    Time frame: week 6, week 14, week 22, week 30, week 38, week 48, week 64, week 80, week 96

  30. Urgency Numerical Rating Score (NRS) and corresponding changes from baseline during follow-up (Weeks 6, week 14, week 22, week 30, week 38, week 48, week 64, week 80 and week 96) in group 1 and group 2

    The Urgency NRS evaluates the participant's sense of urgency to have a bowel movement over the previous 24 hours and is rated on an 11-point Likert scale, from 0 for "no urgency" to 10 for "worst possible urgency"

    Time frame: week 6, week 14, week 22, week 30, week 38, week 48, week 64, week 80, week 96

  31. Inflammatory Bowel Disease Questionnaire (IBDQ) score and corresponding changes from baseline during follow-up (Weeks 30, week 48 and week 96) in group 1 and group 2

    The IBDQ measures health related quality of life in subjects with inflammatory bowel disease. It consists of 32 questions each with a graded response of 1 (worst) to 7 (best). The score ranges from 32 to 224

    Time frame: week 30, week 48, week 96

  32. Time to CD-related complication from randomization through Week 96 in group 1 and group 2

    CD-related complication will be defined as any of the following: (1) CD-related surgery; (2) CD-related hospitalization; (3) CD medication-related complication; (4) CD procedure-related complication; (5) Rescue therapy for a documented CD-related flare e.g., new initiation of an advanced therapy other than VDZ (approved biologic or small molecule), dose escalation of vedolizumab, or dose intensification beyond the dose used at randomization of a corticosteroid after Week 48 or; (6) Other CD-related complication

    Time frame: from randomization through Week 96

  33. Time to each component of CD-related complication in group 1 and group 2

    Time frame: from randomization through Week 96

  34. Percentage of participants who switched to an alternate biologic (yes/no) by Week 48 and Week 96

    Time frame: week 48, week 96

  35. Exposure-adjusted incidence rates of serious adverse events (SAEs), all adverse events (AEs), and AEs of special interest (AESIs) in group 1 and group 2

    Defined as the number of participants experiencing the event per 100 person-years (PYs) of exposure.

    Time frame: up to week 96

07

Study locations

51 of 69 sites recruiting
  • TLC Clinical Research Inc - Los Angeles
    Los Angeles, California 90048, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Medical University of South Carolina (MUSC)
    Charleston, South Carolina 29425, United States
    Not yet recruiting
    • Erin Forster, MD · Principal investigator
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
    Recruiting
    • Bincy Abraham, MD · Principal investigator
  • Concord Repatriation General Hospital
    Concord, New South Wales 2139, Australia
    Recruiting
    • Aviv Puddpedi, MD · Principal investigator
  • Mater Misericordiae Ltd
    South Brisbane, Queensland 4101, Australia
    Recruiting
    • Jakob Begun, MD · Principal investigator
  • Calvary Adelaide Hospital
    Adelaide, South Australia 5000, Australia
    Recruiting
    • Patricia Kaazan, MD · Principal investigator
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
    Recruiting
    • Kate Lynch, MD · Principal investigator
  • The Queen Elizabeth Hospital
    Woodville, South Australia 5011, Australia
    Recruiting
    • Robert Bryant, MD · Principal investigator
  • Northern Hospital Epping
    Epping, Victoria 3076, Australia
    Recruiting
    • Mayur Garg, MD · Principal investigator
  • Austin Health
    Heidelberg, Victoria 3084, Australia
    Recruiting
    • Peter De Cruz, MD · Principal investigator
  • The Alfred Hospital
    Melbourne, Victoria 3004, Australia
    Recruiting
    • Miles Sparrow, MD · Principal investigator
  • Royal Melbourne Hospital
    Melbourne, Victoria, Australia
    Recruiting
    • Zaid Ardalan, MD · Principal investigator
  • Harry Perkins institute of Medical Research - Fiona Stanley Hospital
    Murdoch, Western Australia 6150, Australia
    Recruiting
    • Lena Thin, MD · Principal investigator
  • VITAZ - AZ Nikolaas
    Sint-Niklaas, Antwerpen 9100, Belgium
    Recruiting
    • Tom Holvoet, MD · Principal investigator
  • Imelda Ziekenhuis Bonheiden
    Bonheiden, Antwerp 2820, Belgium
    Recruiting
    • Peter Bossuyt, MD · Principal investigator
  • University Hospital Ghent
    Ghent, East Flanders 9000, Belgium
    Recruiting
    • Triana Lobaton Ortega, MD · Principal investigator
  • UZ Leuven-University Hospital Gasthuisberg
    Leuven, Flemish Brabant 3000, Belgium
    Recruiting
    • Bram Verstockt, MD · Principal investigator
  • AZ Delta - Rumbeke Campus
    Roeselare, West Flanders 8800, Belgium
    Recruiting
    • Filip Baert, MD · Principal investigator
  • ULB Hopital Erasme
    Brussels, 1070, Belgium
    Recruiting
    • Denis Franchimont, MD · Principal investigator
  • University of Calgary
    Calgary, Alberta T2N 4Z6, Canada
    Recruiting
    • Kerri Novak, MD · Principal investigator
  • University of Alberta, Dept of Medicine, Division of Gastroenterology
    Edmonton, Alberta T6G 2X8, Canada
    Recruiting
    • Michal Gozdzik, MD · Principal investigator
  • Viable Clinical Research - Bridgewater
    Bridgewater, Nova Scotia B4V 3N2, Canada
    Recruiting
    • Hughie Fraser, MD · Principal investigator
  • LHSC - University Campus
    London, Ontario N6A 5A5, Canada
    Recruiting
    • Melanie Beaton, MD · Principal investigator
  • LHSC - Victoria Hospital
    London, Ontario N6A 5W9, Canada
    Not yet recruiting
    • Terry Ponich, MD · Principal investigator
  • Toronto Immune and Digestive Health Institute Inc. (TIDHI)
    Toronto, Ontario, Canada
    Recruiting
    • Mark Silverberg, MD · Principal investigator
  • Vojenska nemocnice Brno
    Brno, South Moravian 615 00, Czechia
    Not yet recruiting
    • David Stepek, MD · Principal investigator
  • Fakultni Nemocnice Brno
    Brno, South Moravian 625 00, Czechia
    Not yet recruiting
    • Stefan Konecny, MD · Principal investigator
  • Herlev Hospital
    Herlev, Capital Region 2730, Denmark
    Recruiting
    • Jacob Wium Bjerrum, MD · Principal investigator
  • Nordsjaellands Hospital - Hillerod
    Hillerød, Capital Region 3400, Denmark
    Recruiting
    • Salvatore Leotta, MD · Principal investigator
  • Bispebjerg Hospital
    Copenhagen NV, Capital 2400, Denmark
    Recruiting
    • Kristian Mikkelsen, MD · Principal investigator
  • Hvidovre Hospital
    Hvidovre, Capital 2650, Denmark
    Recruiting
    • Klaus Theede, MD · Principal investigator
  • Aarhus Universitetshospital
    Aarhus, Central Denmark 8200, Denmark
    Recruiting
    • Anders Dige, MD · Principal investigator
  • Randers Regional Hospital
    Randers, Central Denmark 83930, Denmark
    Recruiting
    • Mia Bendix, MD · Principal investigator
  • Sjaellands Universitets hospitall Koge
    Køge, Region Sjælland 4600, Denmark
    Withdrawn

    Not enrolling at this site — choose another above.

  • Svendborg Hospital
    Svendborg, Denmark
    Withdrawn

    Not enrolling at this site — choose another above.

  • Hopital Lyon Sud
    Pierre-Bénite, Auvergne-Rhône-Alpes 69495, France
    Recruiting
    • Stephane Nancey, MD · Principal investigator
  • APHM
    Marseille, Provence-Alpes-Côte d'Azur Region 13015, France
    Recruiting
    • Melanie Serrero, MD · Principal investigator
  • Groupe Hospitalier Prive Ambroise Pare - Hartmann
    Neuilly-sur-Seine, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • Universitatsklinikum Augsburg
    Augsburg, Bavaria 86156, Germany
    Not yet recruiting
    • Elisabeth Schnoy, MD · Principal investigator
  • Universitatsklinkum Frankfurt - Goethe Universitat
    Frankfurt am Main, Hesse 60590, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Klinikum Luneburg
    Lüneburg, Lower Saxony 21339, Germany
    Recruiting
    • Christian Maaser, MD · Principal investigator
  • Universitaetsklinikum Schleswig-Holstein (UKSH)- Campus Kiel
    Kiel, Schleswig-Holstein 24105, Germany
    Recruiting
    • Stefan Schreiber, MD · Principal investigator
  • Universitats Klinikum Freiburg
    Freiburg im Breisgau, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Ospedale Casa Sollievo della Sofferenza IRCCS
    San Giovanni Rotondo, Foggia 71013, Italy
    Recruiting
    • Fabrizio Bossa, MD · Principal investigator
  • Ospedale Luigi Sacco
    Milan, Lombardy 20157, Italy
    Recruiting
    • Giovanni Maconi, MD · Principal investigator
  • Ospedale San Raffaele S.r.I.
    Milan, Milan 20132, Italy
    Not yet recruiting
    • Mariangela Allocca, MD · Principal investigator
  • Policlinico Universitario Agostino Gemelli
    Roma, Rome 00168, Italy
    Recruiting
    • Antonio Gasbarrini, MD · Principal investigator
  • Radboud University Nijmegen Medical Centre
    Nijmegen, Gelderland 6525, Netherlands
    Recruiting
    • Marjolijn Duijvestein, MD · Principal investigator
  • Amsterdam UMC - VU Medisch Centrum
    Amsterdam, North Holland 1081HV, Netherlands
    Recruiting
    • Krisztina Gecse, MD · Principal investigator
  • Erasmus Medisch Centrum (MC)
    Rotterdam, South Holland 3015 GD, Netherlands
    Not yet recruiting
    • Annemarie De Vries, MD · Principal investigator
  • ETZ - St. Elisabeth Hospital
    Tilburg, Netherlands
    Withdrawn

    Not enrolling at this site — choose another above.

  • Oddzial Gastroenterologiczny SP ZOZ w Lecznej
    Łęczna, Gmina Leczna 21-010, Poland
    Recruiting
    • Lukasz Wolanski, MD · Principal investigator
  • SOLUMED Centrum Medyczne
    Poznan, Greater Poland Voivodeship 60-529, Poland
    Recruiting
    • Magdalena Andrzejewska, MD · Principal investigator
  • GASTROMED - Kopon, Zmudzinski I Wspolnicy Sp.j.
    Torun, Kuyavian-Pomeranian Voivodeship 87-100, Poland
    Recruiting
    • Adam Kopon, MD · Principal investigator
  • Melita Medical Sp Zoo
    Wroclaw, Lower Silesian Voivodeship 53-611, Poland
    Recruiting
    • Jaroslaw Leszczyszyn, MD · Principal investigator
  • Bodyclinic Sp.z.o.o. Sp.K
    Warsaw, Masovia 03-712, Poland
    Recruiting
    • Piotr Gietka, MD · Principal investigator
  • WIP Warsaw IBD Point Profesor Kierkus
    Warsaw, Masovia 04-501, Poland
    Recruiting
    • Jaroslaw Kierkus, MD · Principal investigator
  • Centrum Medyczne Medyk
    Rzeszów, Podkarpackie Voivodeship 35-326, Poland
    Recruiting
    • Rafal Filip, MD · Principal investigator
  • Vita Longa Sp. z o.o.
    Katowice, Silesian 40-748, Poland
    Recruiting
    • Przemyslaw Ramos, MD · Principal investigator
  • Sonomed Sp. z o.o. - Centrum Medyczne
    Szczecin, West Pomerianian 71-685, Poland
    Recruiting
    • Anna Wiechowska-Kozlowska, MD · Principal investigator
  • Twoja Przychodnia-Centrum Medyczne Opole
    Opole, Poland
    Withdrawn

    Not enrolling at this site — choose another above.

  • EuroMediCare (EMC) Instytut Medyczny SA
    Wroclaw, 54-144, Poland
    Recruiting
    • Patryk Smolinski, MD · Principal investigator
  • LisbonCentro Hospitalar Lisboa Norte, EPE- Hospital de Santa Maria
    Lisbon, Portugal
    Not yet recruiting
    • Samuel Fernandes, MD · Principal investigator
  • Nottingham University Hospitals NHS Trust - QMC
    Nottingham, East Midlands NG7 2UH, United Kingdom
    Recruiting
    • Sunil Samuel · Principal investigator
  • London North West University Healthcare NHS Trust - Northwick Park Hospital
    Harrow, Middlesex HA1 3UJ, United Kingdom
    Withdrawn

    Not enrolling at this site — choose another above.

  • Western General Hospital
    Edinburgh, EH4 2XU, United Kingdom
    Not yet recruiting
  • Barts Health NHS Trust - The Royal London Hospital
    London, E1 2AJ, United Kingdom
    Recruiting
    • Gareth Parkes, MD · Principal investigator
  • University College London Hospitals NHS Foundation Trust
    London, NW1 2BU, United Kingdom
    Recruiting
    • Paul Harrow, MD · Principal investigator
  • Kings College Hospital NHS Foundation Trust
    London, SE5 9RS, United Kingdom
    Recruiting
    • Polychronis Pavlidis · Principal investigator
08

References and documents

Publications

  • Jairath V, Vuyyuru SK, Zou G, Ma C, Neustifter B, Agboton C, Romo Bautista I, Allocca M, An YK, Begun J, Bryant RV, Danese S, Dubinsky M, Feagan BG, Freire M, Novak KL, Panaccione R, Pudipeddi A, Rubin DT, Sands BE, Sparrow MP, Taylor SA, Gecse KB, Wilkens R, Maaser C. Evaluating treatment to a target of transmural healing in patients with moderately to severely active Crohn's disease: rationale, design and protocol for the randomised controlled VECTORS trial. BMJ Open Gastroenterol. 2026 Feb 20;13(1):e002088. doi: 10.1136/bmjgast-2025-002088. PubMed 41720589 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the results reported in this article may be made available upon reasonable request, subject to review and approval by the study sponsor, execution of a data use agreement, and in accordance with participant consent and applicable privacy and data protection requirements.

Supporting information: Study protocol, Informed consent form, Analytic code

Time frame: 06JAN2026 - 31JAN2029

Access criteria: De-identified individual participant data underlying the results reported in this article may be made available upon reasonable request, subject to review and approval by the study sponsor, execution of a data use agreement, and in accordance with participant consent and applicable privacy and data protection requirements.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Jan 2029, 52 months after the start.

Of 54 non-industry phase 4 interventional studies under Crohn Disease, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 71. This study's planned 52 months is close to that.

Counting every sponsor, half of 70 studies reached it within 56 months; a quarter within 35 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2024
First posted
Feb 14, 2024
StartActual
Aug 7, 2024
Primary completionEst.
Jan 3, 2029
CompletionEst.
Feb 6, 2029
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06257706
Lead sponsor
Alimentiv Inc.
Collaborators
Takeda
Responsible party
Sponsor
First posted
Feb 14, 2024
Start date
Aug 7, 2024
Primary completion
Jan 3, 2029 (estimated)
Completion
Feb 6, 2029 (estimated)
Last update
Jan 15, 2026

Study contacts

Elena van Hest
Contact
elena.vanhest@alimentiv.com
31205630316
Vipul Jairath, MD
principal investigator · Alimentiv Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion